secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-05-06T23:59:59+00:00
Accession:  0001493152-22-012308
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic appoints CMO Fatih Uckun and CRO Seymour Fein effective May 1, 2022
-----------------------------------------------------------------------------

- Fatih Uckun appointed Consulting CMO; $504k/year salary, 70% time commitment.
- Seymour Fein appointed Consulting Chief Regulatory Officer; $180k/year, 10% time.
- Both to lead OT-101 registration trials for DIPG and pancreatic cancer under joint venture.
- Uckun previously CMO at Reven, Ares, Aptevo; Fein has 35+ years and 20+ FDA approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-012308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer